Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How do adenosine A2A receptors regulate motor function?
Akihisa Mori
Parkinsonism & Related Disorders (2020) Vol. 80, pp. S13-S20
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease
Peter Jenner, Akihisa Mori, Stephen Aradi, et al.
Expert Review of Neurotherapeutics (2021) Vol. 21, Iss. 3, pp. 317-333
Open Access | Times Cited: 60
Genetics and Pathogenesis of Dystonia
Mirja Thomsen, Lara M. Lange, Michael Zech, et al.
Annual Review of Pathology Mechanisms of Disease (2023) Vol. 19, Iss. 1, pp. 99-131
Open Access | Times Cited: 39
Metabolic Aspects of Adenosine Functions in the Brain
Mercedes Garcia‐Gil, Marcella Camici, S. Allegrini, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 49
The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease
Akihisa Mori, Jiang‐Fan Chen, Shinichi Uchida, et al.
Molecules (2022) Vol. 27, Iss. 7, pp. 2366-2366
Open Access | Times Cited: 36
Drugs targeting adenosine signaling pathways: A current view
Barbara Kutryb-Zając, Ada Kawecka, Khrystyna Nasadiuk, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115184-115184
Open Access | Times Cited: 17
In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A2AReceptor Antagonist/Inverse Agonist
Yutaro Ohno, Michihiko Suzuki, Hidetsugu Asada, et al.
Molecular Pharmacology (2023) Vol. 103, Iss. 6, pp. 311-324
Closed Access | Times Cited: 12
Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease
Stuart Isaacson, Peter Jenner
Clinical Parkinsonism & Related Disorders (2025), pp. 100303-100303
Open Access
Impact of istradefylline on motor and non-motor symptoms in patients with Parkinson’s disease: Subanalysis of the ISTRA ADJUST PD
Hiroshi Nagayama, Osamu Kano, Renpei Sengoku, et al.
Clinical Parkinsonism & Related Disorders (2025), pp. 100327-100327
Open Access
Macamides as Potential Therapeutic Agents in Neurological Disorders
Karin J. Vera-López, Gonzalo Dávila-Del-Carpio, Rita Nieto-Montesinos
Neurology International (2024) Vol. 16, Iss. 6, pp. 1611-1625
Open Access | Times Cited: 3
Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research
Mohammad Ahmed Khan, Nafis Haider, Tanveer Singh, et al.
Metabolic Brain Disease (2023) Vol. 38, Iss. 3, pp. 873-919
Closed Access | Times Cited: 8
Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery
Javed Ahmad, Nafis Haider, Mohammad Ahmed Khan, et al.
Biochemical Pharmacology (2021) Vol. 195, pp. 114849-114849
Closed Access | Times Cited: 17
Adenosine and adenosine receptors in metabolic imbalance-related neurological issues
Mi‐Hyeon Jang, Juhyun Song
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116996-116996
Open Access | Times Cited: 2
Dietary omega-3 fatty acid deficiency from pre-pregnancy to lactation affects expression of genes involved in hippocampal neurogenesis of the offspring
Vilasagaram Srinivas, Saikanth Varma, Suryam Reddy Kona, et al.
Prostaglandins Leukotrienes and Essential Fatty Acids (2023) Vol. 191, pp. 102566-102566
Closed Access | Times Cited: 6
Anti-parkinsonian activity of the adenosine A2A receptor antagonist/inverse agonist KW-6356 as monotherapy in MPTP-treated common marmosets
Yutaro Ohno, Eri Okita, Mika Kawai-Uchida, et al.
European Journal of Pharmacology (2023) Vol. 950, pp. 175773-175773
Open Access | Times Cited: 5
Randomized controlled trial of KW-6356 monotherapy in patients with early untreated Parkinson's disease
Tetsuya Maeda, Takashi Kimura, Ken-ichiro SUGIYAMA, et al.
Parkinsonism & Related Disorders (2023) Vol. 117, pp. 105907-105907
Open Access | Times Cited: 5
Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease
Rafael Rivas‐Santisteban, Alberto J. Rico, Ana Muñoz, et al.
Neurobiology of Disease (2023) Vol. 188, pp. 106341-106341
Open Access | Times Cited: 5
Efficacy and safety of istradefylline in patients with Parkinson's disease presenting with postural abnormalities: Results from a multicenter, prospective, and open-label exploratory study in Japan
Makio Takahashi, Toshio Shimokawa, Jinsoo Koh, et al.
Journal of the Neurological Sciences (2021) Vol. 432, pp. 120078-120078
Closed Access | Times Cited: 12
The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets
Yutaro Ohno, Eri Okita, Mika Kawai-Uchida, et al.
Journal of Pharmacological Sciences (2023) Vol. 152, Iss. 3, pp. 193-199
Open Access | Times Cited: 4
Intracellular signaling mechanisms that shape postsynaptic GABAergic synapses
Hyeji Jung, Seungjoon Kim, Jaewon Ko, et al.
Current Opinion in Neurobiology (2023) Vol. 81, pp. 102728-102728
Closed Access | Times Cited: 4
Real-world evidence on levodopa dose escalation in patients with Parkinson’s disease treated with istradefylline
Nobutaka Hattori, Daijiro Kabata, Shinji Asada, et al.
PLoS ONE (2023) Vol. 18, Iss. 12, pp. e0269969-e0269969
Open Access | Times Cited: 4
18F-Labeled PET Tracers Specific for Adenosine A2A Receptor: Design, Synthesis, and Biological Evaluation
Tingyu Yang, Wei Zheng, Xuebo Cheng, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 6, pp. 1286-1297
Closed Access | Times Cited: 1
Photochemical affinity switches to resolve ligand dissociation from a G protein-coupled receptor by time-resolved serial crystallography
Jörg Standfuss, Hannah Glover, Torben Saßmannshausen, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Istradefylline/L‐DOPA Parkinson's disease therapy and energy coupling
Naomi Kanzato, Koh Nakachi, Satsuki Mochizuki
Neurology and Clinical Neuroscience (2024) Vol. 12, Iss. 5, pp. 296-305
Open Access | Times Cited: 1
Coffee and multiple sclerosis (MS)
Youssef K. Ghallab, Omnia S. Elassal, Ruth G Mina
Progress in brain research (2024), pp. 57-79
Closed Access | Times Cited: 1
Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST)
Yasushi Shimo, Tetsuya Maeda, Shih‐Wei Chiu, et al.
Parkinsonism & Related Disorders (2021) Vol. 91, pp. 115-120
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top